Literature DB >> 25360802

Severe neurotoxicity following intrathecal methotrexate with nitrous oxide sedation in a child with acute lymphoblastic leukemia.

U Löbel1, J Trah, G Escherich.   

Abstract

Systemic and intrathecal methotrexate is widely used in treatment protocols for childhood acute lymphoblastic leukemia. Its side effects vary in characteristics, intensity and time of onset, and depend on the administration route. Interactions with several drugs are known. Side effects of nitrous oxide sedation, often used for moderately painful procedures, typically occur after long time use and include neurological symptoms. We present a child who experienced a severe and long-lasting neurotoxicity after the third intrathecal application of methotrexate with short sedation by nitrous oxide during induction therapy for acute lymphoblastic leukemia. Symptoms completely resolved after 12 months.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  leukemia; methotrexate; neurotoxicity; nitrous oxide

Mesh:

Substances:

Year:  2014        PMID: 25360802     DOI: 10.1002/pbc.25270

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

1.  Low-level laser or LED photobiomodulation on oral mucositis in pediatric patients under high doses of methotrexate: prospective, randomized, controlled trial.

Authors:  Douglas Magno Guimaraes; Tamara Melo Nunes Ota; Diego Assunção Calixto Da Silva; Fabio De Lucas Da Silva Almeida; Tatiana Dias Schalch; Alessandro Melo Deana; Jose Miguel Alves Junior; Kristianne Porta Santos Fernandes
Journal:  Support Care Cancer       Date:  2021-04-24       Impact factor: 3.603

2.  Severe, Fatal Methotrexate-related Neurotoxicity in 2 Adolescent Patients With ALL.

Authors:  Sarah Dabagh; Henry David; Sarah Young; Andrew Doan; Deepa Bhojwani
Journal:  J Pediatr Hematol Oncol       Date:  2020-11       Impact factor: 1.170

3.  Effect of methotrexate/vitamin B12 on DNA methylation as a potential factor in leukemia treatment-related neurotoxicity.

Authors:  Victoria J Forster; Alex McDonnell; Rachel Theobald; Jill A McKay
Journal:  Epigenomics       Date:  2017-08-15       Impact factor: 4.778

4.  Drug interactions may be important risk factors for methotrexate neurotoxicity, particularly in pediatric leukemia patients.

Authors:  Victoria J Forster; Frederik W van Delft; Susan F Baird; Shona Mair; Roderick Skinner; Christina Halsey
Journal:  Cancer Chemother Pharmacol       Date:  2016-09-22       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.